Answers are grounded in this paper and cite their sources.
Comprehensive analysis shows survival differences in patients with pancreatic ductal adenocarcinoma and brain metastases, suggesting better outcomes with combined therapies.
s Background Pancreatic ductal adenocarcinoma (PDAC) often presents with metastases. Brain metastases are rare, necessitating a thorough analysis of patient profiles and management. Methods Patients with PDAC and brain metastases (2010–2021) were identified from the SEER database. PDAC-specific survival (PSS) was the primary outcome. Survival differences were assessed via Kaplan–Meier analysis, and prognostic factors via Cox regression. Results This study included 113 patients with PDAC brain metastasis, and survival analysis was conducted on 78 eligible patients. The median PSS times were 6 months for brain metastases combined with lung metastases, 5 months for brain-only metastases, 3 months for brain metastases combined with bone metastases, 2 months for brain metastases combined with multiple metastases, and 1.5 months for brain metastases combined with liver metastases. Patients who received both radiotherapy and chemotherapy had better prognoses than those who had received radiotherapy only ( P < 0.001, hazard ratio (HR) = 0.110). Other risk factors were combined with liver metastases (compared with only brain metastasis: P < 0.001, HR = 4.57) and a separated, divorced, or widowed marital status (compared with a married status: P = 0.038, HR = 2.029). Conclusions Patients with PDAC brain metastases combined with liver metastases showed a significantly shorter median PSS time than those with brain metastases only. Patients who had received both chemotherapy and radiotherapy had longer median PSS time than those who had received radiotherapy only. A study with a large sample size is still required.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: